{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=97&state=Ohio",
    "query": {
      "state": "Ohio",
      "city": "Cincinnati",
      "page": 97
    },
    "page_size": 10
  },
  "pagination": {
    "page": 97,
    "page_size": 10,
    "total_count": 10572,
    "total_pages": 1058,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=98&state=Ohio&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cincinnati&page=96&state=Ohio&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:21:50.432Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01526681",
      "title": "Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Peripheral Nerve Injuries"
      ],
      "interventions": [
        {
          "name": "Processed Human Nerve Graft",
          "type": "OTHER"
        },
        {
          "name": "Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.",
          "type": "OTHER"
        },
        {
          "name": "Autogenous Nerve Graft",
          "type": "OTHER"
        },
        {
          "name": "Nerve Tube Conduit",
          "type": "DEVICE"
        },
        {
          "name": "Autologous Breast Reconstruction with Neurotization",
          "type": "PROCEDURE"
        },
        {
          "name": "Autologous Breast Reconstruction without Neurotization",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Axogen Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3126,
      "start_date": "2008-11",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 46,
      "location_summary": "Phoenix, Arizona • Orange, California • San Francisco, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01526681"
    },
    {
      "nct_id": "NCT04173065",
      "title": "A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "VK2809",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viking Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 248,
      "start_date": "2019-11-15",
      "completion_date": "2024-01-26",
      "has_results": false,
      "last_update_posted_date": "2024-06-14",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 68,
      "location_summary": "Madison, Alabama • Glendale, Arizona • Tucson, Arizona + 57 more",
      "locations": [
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173065"
    },
    {
      "nct_id": "NCT00925600",
      "title": "Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer",
        "Cataract",
        "Low Bone Mineral Density",
        "Osteopenia",
        "Osteoporosis",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Denosumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "30 Years to 120 Years · Male only"
      },
      "enrollment_count": 769,
      "start_date": "2009-11-30",
      "completion_date": "2016-05-12",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 52,
      "location_summary": "Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00925600"
    },
    {
      "nct_id": "NCT03274492",
      "title": "A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Polatuzumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Placebo",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Polatuzumab vedotin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2017-11-16",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Duarte, California + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03274492"
    },
    {
      "nct_id": "NCT06105736",
      "title": "Regulating Together in Tuberous Sclerosis Complex",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "TSC",
        "Behavioral Symptoms"
      ],
      "interventions": [
        {
          "name": "Behavioral Intervention in a small group platform",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 105,
      "start_date": "2023-12-20",
      "completion_date": "2026-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 2,
      "location_summary": "Carrboro, North Carolina • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Carrboro",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06105736"
    },
    {
      "nct_id": "NCT01070836",
      "title": "JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "natalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35895,
      "start_date": "2010-03",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-09-29",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 473,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Tucaloosa, Alabama + 386 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Tucaloosa",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01070836"
    },
    {
      "nct_id": "NCT02198664",
      "title": "Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "AR101 - Peanut protein capsule",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aimmune Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "4 Years to 26 Years"
      },
      "enrollment_count": 47,
      "start_date": "2014-08-27",
      "completion_date": "2018-01-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02198664"
    },
    {
      "nct_id": "NCT02313909",
      "title": "Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Acetylsalicylic acid (Aspirin, BAY1019036)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban-Placebo",
          "type": "OTHER"
        },
        {
          "name": "Aspirin-Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 7213,
      "start_date": "2014-12-23",
      "completion_date": "2018-02-15",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 38,
      "location_summary": "Tucson, Arizona • Long Beach, California • Stanford, California + 32 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02313909"
    },
    {
      "nct_id": "NCT01360632",
      "title": "Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder",
        "Depression",
        "Depressive Disorder, Major",
        "Mood Disorders",
        "Mental Disorders"
      ],
      "interventions": [
        {
          "name": "OPC-34712 + ADT",
          "type": "DRUG"
        },
        {
          "name": "Placebo + ADT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1539,
      "start_date": "2011-06",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2016-01-01",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 52,
      "location_summary": "Birmingham, Alabama • Costa Mesa, California • Glendale, California + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01360632"
    },
    {
      "nct_id": "NCT06369298",
      "title": "Study of JK07 in Patients With Chronic Heart Failure",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure With Reduced Ejection Fraction",
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "JK07",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Salubris Biotherapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 282,
      "start_date": "2024-03-28",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-19T05:21:50.432Z",
      "location_count": 51,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06369298"
    }
  ]
}